This site is intended for health professionals only

Published on 29 January 2015

Share this story:
Twitter
LinkedIn

Accord Healthcare launches their first biopharmaceutical product in Europe: Accofil® (filgrastim)

Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia.

 

Accofil® is a biopharmaceutical product with the same range of indications as Neupogen® (filgrastim) and will offer patients comparable quality, safety and efficacy combined with cost-effectiveness.

 

Therapeutic Indications (1)
Accofil® is indicated for the treatment of:

Accord Healthcare is pleased to announce the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia.

 

Accofil® is a biopharmaceutical product with the same range of indications as Neupogen® (filgrastim) and will offer patients comparable quality, safety and efficacy combined with cost-effectiveness.

 

Therapeutic Indications (1)
Accofil® is indicated for the treatment of:

  • Reduction in the duration of neutropenia and the incidence of febrile neutropenia.
  • Mobilisation of peripheral blood progenitor cells.
  • Severe congenital, cyclic, or idiopathic neutropenia.
  • Persistent neutropenia in patients with advanced HIV infection.

 

For full text of indications, please refer to the EMA website (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003956/WC500176638.pdf).

 

Presentation
Accofil® is available in prefilled syringes in two presentations, both available in packs of one and five prefilled syringes:

  • 30MU/0.5ml.
  • 48MU/0.5ml.

 

Product Features
Accofil® has incorporated additional features for improved patient safety and better product handling.

  • Class-leading stability data* – 15 days physico-chemical stability at room temperature.
  • Clear graduation on syringe to aid accurate dosing and minimise the risk of errors in administration.
  • Passive needle guard protection device to reduce needle stick injuries, minimising the risk of blood borne infections.
  • Strength colour differentiation to improve identification.
  • Individual blister packaging to preserve product integrity and allow storage optimisation.
  • Packaging design with safety features that may improve handling.

*According to authorised SmPCs

 

Mr Binish Chudgar, Vice Chairman and Managing Director commented “The launch of Accofil® demonstrates Accord Healthcare’s commitment to bringing high quality and affordable biopharmaceutical products to the European market.  We are proud that Accofil®, which was developed by our own research scientists, manufactured at our GMP approved biopharmaceutical site, and has been available for ten years in other countries, showcases our expertise in biopharmaceutical development and manufacture.  This is the first of many biological products we are in the process of bringing to the EU market over the coming years”.

 

Accord Healthcare
Accord Healthcare is one of the fastest growing companies in the Europe.  Its product portfolio has grown 713% since the first Accord product was launched in Europe in August 2008 and annual average growth has exceeded 40%.

 

Accord Healthcare is a young dynamic company that since the beginning of its commercial activities in business, retail and hospital, has demonstrated dramatic growth and evolution of its product range.

 

Accord Healthcare’s strategy is to be involved in all the aspects of brining high quality pharmaceuticals to more patients from clinical concept to end-user.  By owning all steps of the pharmaceutical development and production process, Accord Healthcare can bring high quality medicines to patients faster, more economically and with greater innovation than their competitors. It is involved in the manufacturing and distribution of pharmaceutical products to over 60 markets worldwide.

 

Further information:
http://www.accord-healthcare.eu

 

Reference:

  1. EPAR. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_Initial_authorisation/human/003956/WC500170180.pdf.


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn